The Therapeutic Goods Administration (TGA) are aiming to remove unnecessary duplication in assessing therapeutic goods in Australia where they have been approved elsewhere in the world. New assessment protocols will allow changes to streamline the process and use global examples as a precedent.
The move is expected to streamline access in Australia to new medicines and devices after research showed that many Australian patients waited up to 15 months compared to Europe and the USA as many drug companies delayed bringing their business to Australia.
The move makes sense to the industry and with patient care at the heart of the decision it comes as a win for many Australian patients.
